Daniel Cohen

Daniel Cohen has a strong background in biotech investing. Daniel started their career as a Biotech Investor at Lumira Capital from May 2016 to August 2017. Daniel then moved on to become a Biotech Investor at Front Row Ventures from March 2017 to August 2018, where they helped build the life sciences strategy. In September 2018, they co-founded Valence Discovery and served as the CEO, leading the company's efforts to improve human health through computation. Valence was later acquired by Recursion in May 2023.

Daniel Cohen has a Bachelor's degree in Cognitive Science from McGill University. Daniel also holds a Master's degree in Computational Neuroscience from the same institution.